‘A Real-but-Vanilla Commercial Dispute’: What We Heard This Week

“The underlying case is a real-but-vanilla commercial dispute.” — Christopher Robertson, JD, PhD, of Boston University, discussing a medical software company’s lawsuit against a former collaborator, who helped launch a rival platform.

“It seems that people haven’t bought into [the initial report], and now they’re back-tracking.” — Steven Kahn, MBChB, of the University of Washington in Seattle, on fallout from the American Diabetes Association’s investigation into five members ousted from its annual meeting.

“The end point for success of naloxone is not waking up, it’s breathing.” — Lewis Nelson, MD, of Charles E. Schmidt College of Medicine at Florida Atlantic University in Boca Raton, discussing naloxone’s efficacy against overdoses of cychlorphine, a novel synthetic opioid.

“For the first time, this study provides robust evidence in humans supporting a potentially protective role for CO [carbon monoxide] in Parkinson’s.” — Clara Bueno Lopez, MSc, of the University of Oxford in England, on research linking higher carbon monoxide exposure to a lower risk of Parkinson’s disease in non-smokers.

“Girls and boys are now equally likely to take their own lives.” — Jean Twenge, PhD, of San Diego State University, on the closing gender gap in suicide rates among adolescents ages 10 to 14 years.

“I wonder if the rate will go down more with use of GLP-1 agonists.” — Michael Gibson, MD, PhD, of Vanderbilt University Medical Center in Nashville, Tennessee, on changes in esophageal cancer incidence over time.

“If the underlying governance remains fragmented, we should expect inconsistencies like this to continue to emerge.” — Macey Levan, JD, PhD, of NYU Grossman School of Medicine in New York City, on a federal report showing Medicare spent nearly $400 million on unused donor organs.